Measuring bronchodilation in COPD clinical trials

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology
• Clinical Trial Methodology

Background:

• Chronic Obstructive Pulmonary Disease (COPD) management relies on assessing bronchodilator response.
• Accurate and sensitive measurement techniques are crucial for clinical trials evaluating COPD treatments.
• Existing methods like spirometry may have limitations in detecting subtle bronchodilatory effects.

Purpose of the Study:

• To compare the variability and sensitivity of impulse oscillometry, plethysmography, and spirometry.
• To identify the most effective technique for measuring bronchodilation in COPD clinical trials.
• To guide the selection of optimal pulmonary function tests for COPD research.

Main Methods:

• Twenty-four COPD patients underwent repeated measurements of impulse oscillometry (R5, X5, RF), plethysmography (Raw, sGaw), and spirometry (FEV1, FVC, MMEF) to assess variability.
• Ascending doses of salbutamol (20-800 µg) were administered, with pulmonary function tests repeated after each dose.
• Sensitivity was determined by identifying the lowest dose causing statistically significant changes exceeding intra-subject variability.

Main Results:

• Impulse oscillometry (X5, RF) and plethysmography (sGaw) detected significant bronchodilation after 20 µg salbutamol.
• Impulse oscillometry (R5) and plethysmography (Raw) showed significant effects after 50 µg.
• Spirometry (FEV1) was less sensitive, requiring 100 µg to detect significant bronchodilation.

Conclusions:

• Impulse oscillometry and plethysmography are more sensitive than spirometry for assessing bronchodilation in COPD.
• These techniques should be preferred for measuring bronchodilator response in COPD clinical trials.
• The findings support the use of oscillometry and plethysmography for enhanced detection of treatment effects in COPD research.